key: cord-0934752-obls8umo authors: Cozzi, Emanuele; Faccioli, Eleonora; Marinello, Serena; Loy, Monica; Congedi, Sabrina; Calabrese, Fiorella; Romagnoli, Micaela; Cattelan, Anna Maria; Rea, Federico title: COVID‐19 pneumonia in lung transplant recipients: report of two cases date: 2020-05-12 journal: Am J Transplant DOI: 10.1111/ajt.15993 sha: b71f57a2671ef8a31b22837540ebe5cbc7616ec1 doc_id: 934752 cord_uid: obls8umo Coronavirus disease 2019 (COVID‐19) has been declared pandemic since March 2020. In Europe, Italy has been the first nation affected by this infection. In this paper we report anamnestic data, clinical features and therapeutic management of two lung transplant recipients with confirmed COVID‐19 pneumonia. Both patients were in good clinical conditions prior to the infection and were on immunosuppression with calcineurin inhibitors (CNI), mycophenolate mofetil and corticosteroids. Whilst mycophenolate mofetil was withdrawn in both cases, CNI were suspended only in the second patient. The first patient always maintained excellent oxygen saturation throughout hospitalization with no need for additional oxygen therapy. He was discharged with a satisfactory pulmonary function and a complete resolution of radiological and clinical findings. However, at discharge SARS‐CoV‐2 RNA could still be detected in the nasopharyngeal swab and in the stools. The second patient required mechanical ventilation, had a progressive deterioration of his clinical conditions and had a fatal outcome. Further insight into SARS‐CoV‐2 infection is eagerly awaited to improve the outcome transplant recipients affected by COVID‐19 pneumonia. A pneumonia of unknown origin, detected in Wuhan (China), was first reported to the World Health Organization (WHO) on 31 st December 2019. On 9 th January 2020, a new strain of coronavirus (SARS-CoV-2) was identified as the etiologic agent of this novel respiratory disease called COVID-19. Since then, the infection has spread in more than 200 countries, becoming pandemic in March 2020 with a total of 2.078.605 confirmed cases and 139.515, deaths according to the latest WHO report (17 th April 2020) [1] . Italy has been the first European country confronted with the COVID-19 infection, with the first two cases reported on 31 st January 2020. To date (17 th April 2020), according to latest report of the Italian Ministry of Health a total of 168.941 cases and 22.170 deaths have been confirmed [2] . In the last two months, the country has faced a dramatic crisis that has heavily impacted the National Health Care System (that collapsed in some regions), the national economy and the personal relationships. SARS-CoV-2 causes illnesses with different degrees of severity [3] . COVID-19 infection is commonly characterized by fever and upper airway manifestations such as dry cough and dyspnoea. Other symptoms reported include headache, myalgia, hyposmia, hypogeusia, and gastrointestinal disorders [4] . The virus has been isolated in nasopharyngeal and oropharyngeal swabs as well as in stool samples, saliva and cerebrospinal fluid. The virus is predominantly transmitted through respiratory droplets or through direct contact. This article is protected by copyright. All rights reserved Chest X-ray showed the presence of ground-glass opacities in the bases of both lungs, with apparent left pulmonary thickening. Furthermore, several laboratory abnormalities could be observed. In particular, inflammation markers were moderately elevated (CRP: 17 mg/L; procalcitonin: 2,55 ug/L); there was a thrombocytopenia (56x10 9 cells/L); elevated D-dimer levels (301 ug/L) and normal fibrinogen levels 2,20 g/L. On D4, a high resolution CT showed the presence of many ground-glass opacities in the peripheral site of all lung lobes except for the apical ones; many peri-broncho-vasal consolidations with confluent aspect to basal segments of left lower lobe, with notes of air bronchogram (Supplementary Figure 1 ). In the light of his overall clinical conditions, the risk of potential drug interactions with ongoing treatments and the lack of specific recommendations for COVID-19 patients on dialysis, no anti-viral therapies or hydroxychloroquine were administered. Blood cultures were negative for both bacteria and fungi. In addition, the following precautionary measures were put in place: first, the Quinton catheter was removed; second, due to its possible contribution to the fever and presence of a concurrent bacterial superinfection, the patient received meropenem for nine days associated with tigecycline for seven days. During his hospital stay, the patient continued enoxaparin and his dialysis treatment. The clinical conditions did not deteriorate and the patient always maintained good oxygen saturation (SaO2>95%) with no need for additional oxygen therapy. The patient was discharged on D15 in good general conditions with no fever, no cough or other symptoms and a clear chest X-ray. Immunosuppression at that time was based on tacrolimus (0,5 mg x 2/day) and corticosteroids (7,5 mg/day). At discharge and 72 hours later, the nasopharyngeal swabs were still positive for SARS-CoV-2 RNA although the CT scan was clear and did no show particular alterations (Supplementary Figure 2) . Furthermore, at that time the patient also had a mild diarrhea and SARS-CoV-2 could be isolated from the stools. On D33, a nasopharyngeal swab was still positive, whilst on D37 both nasopharyngeal and rectal swabs were found to be negative. The second case is a 71-year-old man who underwent bilateral lung transplantation due Table 1 and 2, respectively. coronaviruses, such as SARS and MERS epidemics [5] . In contrast, since its initial detection in Wuhan at the end of last year, at least 21 cases of COVID-19 disease in transplant patients have been reported [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] . To date these cases have primarily involved kidney, liver, bone marrow and cardiac allograft recipients whilst this case report describes two lung transplant recipients affected by COVID-19 pneumonia. Unquestionably, it is far too premature to draw any meaningful conclusion out of these two cases. Still these two patients allow us to make at least five important considerations This article is protected by copyright. All rights reserved Control [3] . Fourth, viral shedding and infectivity in transplanted patients may not be substantially different from that observed in the general population [20] . Finally, it is yet unknown whether recovery from COVID-19 pneumonia will be associated with a faster progression to chronic lung allograft dysfunction (CLAD). In conclusion, our data suggest that the outcome of COVID-19 pneumonia in lung transplant recipients is not invariably associated with fatal outcome. Furthermore, our Case Report also suggests that complete withdrawal of immunosuppression is not a mandatory requirement to enable the clinical recovery of lung transplant recipients affected by COVID-19 pneumonia. The authors of this manuscript have no conflicts to disclose as described by the This article is protected by copyright. All rights reserved Accepted Article WHO Coronavirus disease situation reports Italian Ministry of Health Coronavirus situation reports Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the chinese center for disease control and prevention Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet MERS CoV infection in two renal transplant recipients: case report SARS Cov2 infection in a renal transplanted patients. A case report COVID-19 in post-transplantation patients-report of two cases COVID-19 in kidney transplant recipients Accepted Article This article is protected by copyright. All rights reserved Case report of COVID-19 in a kidney transplant recipient: does immunosuppression alter the clinical presentation? Successful recovery of COVID-19 pneumonia in a renal transplant recipient with long-term immunosuppression COVID-19 infection in kidney transplant recipients Immunosuppressive therapy maintenance in a kidney transplant recipient SARS-CoV2 pneumonia: a case report Novel Coronavirus (SARS-CoV-2) infection in a renal transplant recipient: case report Successful treatment of severe COVID-19 pneumonia in a liver transplant recipient Fatal outcome in a liver transplant recipient with COVID-19 Perioperative presentation of COVID 19 disease in a liver transplant recipient. Hepathology First cases of COVID-19 in heart transplantation from China Dysregulation of immune response in patients with COVID-19 in Wuhan, China Management of patients on dialysis and with kidney transplant during COVID-19 coronavirus infection pandemic in The duration of viral shedding of discharged patients This article is protected by copyright. All rights reserved The data that support the findings of this study are openly available. Please see the list of references in our paper.